← All trials
NCT04646590
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2020
- Primary completion
- Apr 30, 2022
- Completion date
- Apr 30, 2022
- First posted
- Nov 30, 2020
- Last posted
- Dec 17, 2020
- Enrollment
- 29000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.